Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov
ABSTRACT Background Patient‐reported adverse events (AEs) may be a useful adjunct to clinician‐assessed AEs for assessing tolerability in early phase, dose‐finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov to describe trends in patient‐reported outcome (PRO) use. Methods DFOTs...
Guardado en:
Autores principales: | Julia Lai‐Kwon, Zhulin Yin, Anna Minchom, Christina Yap |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a51234f7e1fc4d6a9aa857b6e3ea186e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov
por: Kentaro Sakamaki, et al.
Publicado: (2021) -
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Yang Hu, et al.
Publicado: (2021) -
Overview of Clinical Trials on Type 2 Diabetes Mellitus: A Comprehensive Analysis of the ClinicalTrials.gov Database
por: Long J, et al.
Publicado: (2021) -
Obstacles to the reuse of study metadata in ClinicalTrials.gov
por: Laura Miron, et al.
Publicado: (2020) -
Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic review
por: Cherie L. Hauck, et al.
Publicado: (2021)